upadacitinib,adalimumab
abbvie
[' psa', 'upadacitinib', ' ada ']
congress #acr22 | andrea rubbert-roth presented a poster about malignancy rates in pts with ra, psa, and as from the select clinical trials of upadacitinib vs ada and mtx. in #psoriaticarthritis pts treated with upa, age was found to be a risk factor for malignancy. 
The Psoriasis and Psoriatic Arthritis Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education.